2SEVENTY Bio, Inc.
Records under this name other than the patents 2SEVENTY Bio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 22 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,196,444 | Multipartite Signaling Proteins and Uses Thereof now held by Regeneron Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 10,428,142 | Multipartite Signaling Proteins and Uses Thereof now held by Regeneron Pharmaceuticals, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 10,457,731 | Multipartite Signaling Proteins and Uses Thereof now held by Regeneron Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 11,530,265 | Multipartite Signaling Proteins and Uses Thereof now held by Regeneron Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 12,760,099 | Multipartite Signaling Proteins and Uses Thereof now held by Regeneron Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 11,912,746 | PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use now held by Regeneron Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 12,391,734 | PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use now held by Regeneron Pharmaceuticals, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,264,343 | TCRa HOMING ENDONUCLEASE VARIANTS now held by Regeneron Pharmaceuticals, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,365,711 | Tgfbeta Signal Convertor now held by Regeneron Pharmaceuticals, Inc. In force · Low confidence | In force | Low confidence | |
| US 10,927,367 | CBLB Endonuclease Variants, Compositions, and Methods of Use now held by Regeneron Pharmaceuticals, Inc. In force · Low confidence | In force | Low confidence |